Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06048094 · ClinicalTrials.gov registry record · Phase 1
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
A Phase 1 study of Brain Metastases and Brain Cancer, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06048094: Recruiting Phase 1 study of Brain Metastases and Brain Cancer, sponsored by Baptist Health South Florida.
NCT06048094 is a Phase 1 study of Brain Metastases and Brain Cancer that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 46 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06048094, a Phase 1 study of Brain Metastases and Brain Cancer, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Primary Outcome
Each 18F-fluciclovine PET will undergo quantitative image analysis by the study nuclear medicine physician. The lesion on each PET will be correlated with the lesion on the corresponding contrast-enhanced MRI and will be delineated. The SUVpeak will be calculated for the pre-SRS and post-SRS imaging studies, as well as the percent change from pre to post will be calculated. Assuming SRS reduces the tumor size, a negative percent change (decrease) is expected.
Conditions Studied
Interventions
- DRUG 18F fluciclovine
Study Locations (1)
Florida
- Miami Cancer Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT06048094 shows while recruiting
NCT06048094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which 18F fluciclovine is the first listed.
NCT06048094 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06048094 about?
NCT06048094 is a clinical study titled "18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery". This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis afte...
What is the current status of trial NCT06048094?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2024-04-11. Estimated completion is 2027-05.
What conditions does trial NCT06048094 study?
This clinical trial studies the following conditions: Brain Metastases, Brain Cancer, Brain Metastases, Adult.
What interventions are being tested in trial NCT06048094?
The interventions under investigation include: 18F fluciclovine (DRUG).
Who is sponsoring clinical trial NCT06048094?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06048094 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06048094's enrollment target sits among peer trials
46 33rd of 67 higher than 34 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RECRUITING · Phase 1
-
Phase I Study of Fractionated Stereotactic Radiation Therapy
RECRUITING · Phase 1
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
-
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI